X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GFH925 (IBI351) is a novel small molecule KRAS G12C inhibitor, which is being evaluated for the treatment of patients with colorectal cancer with KRAS G12C mutations.
Lead Product(s): IBI351
Therapeutic Area: Oncology Product Name: GFH925
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2024
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory peripheral T-cell lymphomas and acute myeloid leukemia .
Lead Product(s): SLS009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2024
Details:
Under the collaboration, Verastem selects a potential best-in-class KRAS G12D oral selective small molecule inhibitor, GFH375/VS-7375, as the lead program for its discovery and development for therapeutics targeting KRAS mutations.
Lead Product(s): VS-7375
Therapeutic Area: Oncology Product Name: GFH375
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Verastem Oncology
Deal Size: $625.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2023
Details:
GFH925 (IBI351) is a novel small molecule KRAS G12C inhibitor, which is being evaluated for the treatment of patients with advanced solid tumors with KRAS G12C mutations.
Lead Product(s): IBI351
Therapeutic Area: Oncology Product Name: GFH925
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2023
Details:
SLS009 (GFH009) is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of relapsed/refractory PTCL (peripheral T-cell lymphomas).
Lead Product(s): GFH009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
The collaboration is designed to allow Verastem the flexibility of a milestone-based option to license up to three compounds. The licenses would give Verastem development and commercialization rights outside of China while GenFleet would retain rights inside of China.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Verastem Oncology
Deal Size: $637.0 million Upfront Cash: $11.5 million
Deal Type: Collaboration August 28, 2023
Details:
GFH009 is a small molecule, highly selective CDK9 inhibitor, demostrated anti-tumor activity in the study being investigated for the treatment of acute myeloid leukemia (AML).
Lead Product(s): GFH009
Therapeutic Area: Oncology Product Name: GFH009
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Sellas Life Sciences Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
GFH925 inhibits the GTP/GDP exchange, an essential step in pathway activation. Subsequently, GFH925 inhibits the downstream signal pathway to induce tumor cells' apoptosis and cell cycle arrest. Being developed for advanced NSCLC patients harboring KRASG12C mutation.
Lead Product(s): GFH925,Cetuximab
Therapeutic Area: Oncology Product Name: GFH925
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
By covalently and irreversibly modifying the cysteine residue of KRAS G12C protein, GFH925 inhibits the GTP/GDP exchange, an essential step in pathway activation.
Lead Product(s): GFH925,Cetuximab
Therapeutic Area: Oncology Product Name: GFH925
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 19, 2022
Details:
Preclinical data demonstrated GFH312 is able to inhibit RIPK1 kinase activity in human cells, down-regulate RIPK1 phosphorylation in animal models and curb the inflammatory response of animals' nervous system.
Lead Product(s): GFH312
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GFH312
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
